Araştırma Makalesi
Yıl 2022,
, 338 - 342, 31.12.2022
Öz
Kaynakça
- Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. 68(6): p. 394-424.
- Kasper, D., et al., Harrison's principles of internal medicine, 19e. Vol. 1. 2015: Mcgraw-hill New York, NY, USA.
- Travis, W.D., E. Brambilla, and G.J.J.J.C.O. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013. 31(8): p. 992-1001.
- Bunn, P.A., Jr., Triplet combination chemotherapy and targeted therapy regimens. Oncology (Williston Park), 2001. 15(3 Suppl 6): p. 26-32.
- Schabath, M.B., M.L.J.C.e. Cote, biomarkers, and prevention, Cancer progress and priorities: lung cancer. 2019. 28(10): p. 1563-1579.
- Scagliotti, G., et al., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 2010. 28(11): p. 1835-42.
- Ciccia, A. and S.J. Elledge, The DNA damage response: making it safe to play with knives. Mol Cell, 2010. 40(2): p. 179-204.
- Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012. 13(3): p. 239-246.
- Abdel-Rahman, L.H., et al., Synthesis, physicochemical studies, embryos toxicity and DNA interaction of some new Iron (II) Schiff base amino acid complexes. 2013. 1040: p. 9-18.
- Felip, E. and R.J.E.r.o.m.d. Rosell, Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. 2007. 7(3): p. 261-268.
- Tomas, L. and D.W.J.S. Richard, Quality control by DNA repair. 1999. 286(5446): p. 1897-1905.
- Fagbemi, A.F., B. Orelli, and O.D.J.D.r. Schärer, Regulation of endonuclease activity in human nucleotide excision repair. 2011. 10(7): p. 722-729.
- Reed, E.J.C.t.r., Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. 1998. 24(5): p. 331-344.
- Simon, G.R., et al., ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. 2005. 127(3): p. 978-983.
- Cozzi, P.G.J.C.S.R., Metal–Salen Schiff base complexes in catalysis: practical aspects. 2004. 33(7): p. 410-421.
- Martin, L.P., T.C. Hamilton, and R.J.J.C.c.r. Schilder, Platinum resistance: the role of DNA repair pathways. 2008. 14(5): p. 1291-1295.
- Olaussen, K.A., et al., DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 2006. 355(10): p. 983-991.
- Zhao, H., et al., Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. 2014. 35(12): p. 12679-12688.
- Olaussen, K.A., et al., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 2006. 355 10: p. 983-91.
Yıl 2022,
, 338 - 342, 31.12.2022
Öz
Objective: Cancer arises as a result of the failure of the mechanisms controlling normal division in a group of cells. It is known that some new synthesis compounds intended for use in cancer treatment have anti-fungal, anti-bacterial, anti-carcinogenic effects. In this study, it was aimed to apply the newly synthesized B-108 compound to the A-549 cell line and then to investigate the effect of this compound on the ERCC1 gene expression profile.
Materials and Methods: Firstly, compound B-108 was synthesized in our study. Afterwards, this synthesized molecule was applied in eight different concentrations (1-100 μg/ml) in A-549 cell line and 3-(4,5-dimethylthiazol-2-yl)-2,5-yl for 24 hours, 48 hours and 72 hours. Anticancer activities were determined using diphenyltetrazolium bromide (MTT) method. Expression level of DNA repair gene (ERCC1) was determined using RT-PCR method.
Results: As a result, it was determined that the molecule applied to the A-549 cell line showed the highest activity after 72 hours of incubation. It was observed that the ERCC1 gene expression of the molecule applied on lung cancer was lower than the control group.
Discussion: Considering the current study results, low expression of ERCC1 shows that compound B-108 correlates with overall survival on lung cancer cells.
Anahtar Kelimeler
Kaynakça
- Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018. 68(6): p. 394-424.
- Kasper, D., et al., Harrison's principles of internal medicine, 19e. Vol. 1. 2015: Mcgraw-hill New York, NY, USA.
- Travis, W.D., E. Brambilla, and G.J.J.J.C.O. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 2013. 31(8): p. 992-1001.
- Bunn, P.A., Jr., Triplet combination chemotherapy and targeted therapy regimens. Oncology (Williston Park), 2001. 15(3 Suppl 6): p. 26-32.
- Schabath, M.B., M.L.J.C.e. Cote, biomarkers, and prevention, Cancer progress and priorities: lung cancer. 2019. 28(10): p. 1563-1579.
- Scagliotti, G., et al., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 2010. 28(11): p. 1835-42.
- Ciccia, A. and S.J. Elledge, The DNA damage response: making it safe to play with knives. Mol Cell, 2010. 40(2): p. 179-204.
- Rosell, R., et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012. 13(3): p. 239-246.
- Abdel-Rahman, L.H., et al., Synthesis, physicochemical studies, embryos toxicity and DNA interaction of some new Iron (II) Schiff base amino acid complexes. 2013. 1040: p. 9-18.
- Felip, E. and R.J.E.r.o.m.d. Rosell, Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. 2007. 7(3): p. 261-268.
- Tomas, L. and D.W.J.S. Richard, Quality control by DNA repair. 1999. 286(5446): p. 1897-1905.
- Fagbemi, A.F., B. Orelli, and O.D.J.D.r. Schärer, Regulation of endonuclease activity in human nucleotide excision repair. 2011. 10(7): p. 722-729.
- Reed, E.J.C.t.r., Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. 1998. 24(5): p. 331-344.
- Simon, G.R., et al., ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. 2005. 127(3): p. 978-983.
- Cozzi, P.G.J.C.S.R., Metal–Salen Schiff base complexes in catalysis: practical aspects. 2004. 33(7): p. 410-421.
- Martin, L.P., T.C. Hamilton, and R.J.J.C.c.r. Schilder, Platinum resistance: the role of DNA repair pathways. 2008. 14(5): p. 1291-1295.
- Olaussen, K.A., et al., DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 2006. 355(10): p. 983-991.
- Zhao, H., et al., Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. 2014. 35(12): p. 12679-12688.
- Olaussen, K.A., et al., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. 2006. 355 10: p. 983-91.
Toplam 19 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Temel Tıp Bilimleri Araştırma Yazıları |
| Yazarlar | |
| Yayımlanma Tarihi | 31 Aralık 2022 |
| Kabul Tarihi | 19 Aralık 2022 |
| Yayımlandığı Sayı | Yıl 2022 |